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of life than Whites even when their health status is equal. This
may lead to racial differences regarding optimal decision making
and conclusions based on cost-effectiveness analysis.
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Pain is widespread. Many scales have been used for measuring
clinical outcomes of pain, but few are preference-based instru-
ments. OBJECTIVES: To compare scores derived from the Box-
Score-11 (BS-11), a clinical scale widely used for measuring pain,
and the Pain attribute (PA) of the Health Utilities Index (HUI-
III), a preference-based instrument. METHODS: Patients (≥18
years) were recruited from pain clinics in four Canadian metro-
politan areas (Toronto, Ottawa, Edmonton, Vancouver) and
were administered both scales, assessing their average pain level
over the previous four weeks. Kendall’s tau-b was calculated
between score sets and the proportions of the scores derived from
the BS-11 that mapped onto each of the ﬁve PA scores of the
HUI-III. RESULTS: Of 516 questionnaires completed, 6 had
missing information, leaving 510 for analysis. The average age
was 49.5 ± 11.9 years; 70% were female. Tau-b was reasonably
large and statistically = 0.685, Ptsigniﬁcant between the scales
(<0.001). No patients scored 0 on either scale, as only patients
with pain were included. Two patients scored 1 and yielded
inconclusive results. All, except one, of the remaining BS-11
scores mapped at ≥60% onto PA scores of the HUI-III respec-
tively: 2 to 2, 3 to 2, 4 to 3, 5 to 3, 7 to 4, 8 to 4, 9 to 5 and
10 to 5; 6 on the BS-11 was mapped onto 4 on the HUI-III with
53% of answers. Scores 2 and 10 had best mapping (88% and
94%). The overall correspondence was considered excellent.
CONCLUSIONS: This study demonstrated that scores from the
BS-11 can be mapped onto the PA component of the HUI-III.
RESPIRATORY DISORDERS
RS1
TRENDS IN MEDICATION PRESCRIBING FOR CHILDREN
WITH SLEEP DISORDERS IN US OUTPATIENT SETTINGS
Rasu RS1, Balkrishnan R2, Nahata MC2
1University of Missouri Kansas City, Kansas City, MO, USA, 2The Ohio
State University College of Pharmacy, Columbus, OH, USA
OBJECTIVES: This study examined trends in physician-pre-
scribing of medications for children with sleep difﬁculties in out-
patient settings in the Unites States. Additionally, this study also
explored the incidence of physician-prescribing patterns of high
abuse-potential medications for children, and compared pre-
scribing trends in children versus adults. METHODS: This cross-
sectional study used data from the National Ambulatory Medical
Care Survey (NAMCS) from 1993–2003. Patient aged <18 years
were included in the study sample. We compared this sample to
the sample of patients aged 18 years and older. Ofﬁce visits were
considered related to sleep difﬁculties if relevant ICD-9 codes
were recorded and if sleep difﬁculties was reported as the reason
for the visit. Medications were retrieved using the NAMCS drug
codes, and all analyses were weighted to make national esti-
mates. RESULTS: From 1993 to 2003, approximately one
million visits were made for sleep-related difﬁculty in children.
Nearly two-thirds (63%) of these visits were related to male chil-
dren and 26% of these visits were by children aged less than
three years. Family practice and internal medicine physicians
accounted for 21% of the patient visits. Only 2% of visits in
children resulted in a prescription for a medication compared to
over half the adult population. Similar trends were observed with
the prescription of high-abuse potential medications, where
adults were 35 times more likely to receive prescriptions of med-
ications with very high abuse potential. There were no time-
related differences observed in these prescribing patterns.
CONCLUSION: The ﬁndings of this study seem to suggest that
a great deal of caution is being exercised by physicians while 
prescribing medications for sleep difﬁculties in children in US
outpatient settings, since most of the visits do not result in med-
ication prescription, unlike trends observed in adult patients with
similar diagnoses in the same treatment setting.
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OBJECTIVE: To compare treatment costs and cost-effectiveness
of telithromycin versus other commonly-prescribed therapies for
community-acquired pneumonia (CAP). METHODS: We devel-
oped an economic model to estimate the costs of treating CAP
using a utilization-based deﬁnition of therapy failure, deﬁned 
as respiratory-related hospitalization, ER visit, receipt of 
second antibiotic, or >1 return ofﬁce visits within 30 days of
therapy initiation. Probability of failure was estimated for 
amoxicillin/clauvulanate, azithromycin, clarithromycin and 
ﬂuoroquinolones from a longitudinal database; estimates were
adjusted using propensity scores based on patient characteristics
and prior utilization patterns. Probabilities for telithromycin
were estimated using relative risks for each outcome versus clar-
ithromycin from a published clinical trial. Costs of initial therapy
and costs of failure were derived from the longitudinal database;
probability of clinical cure was estimated from published clini-
cal trials. The model was used to estimate 30-day direct treat-
ment costs, and cost-effectiveness as incremental cost per clinical
cure. We used second-order Monte Carlo simulation to evaluate
the effect of uncertainty in key model parameters on our ﬁnd-
ings. RESULTS: In base-case analyses, telithromycin had the
lowest overall treatment costs at $174/treated patient, followed
by azithromycin ($219), clarithromycin ($262) ﬂuoroquinolones
($315), and amoxicillin/clauvulanate ($340). Clarithromycin
had a slightly higher probability of clinical cure (92.1%) than
telithromycin (90.5%) but at an additional cost of $5444/cure.
Fluoroquinolones had a slightly higher probability of clinical
cure (92.3%) than clarithromycin at a cost of $24,098/cure.
Azithromycin and amoxicillin/clauvulanate were dominated.
Alternative analyses using AWP and WAC to estimate drug costs
yielded similar results. Probabilistic sensitivity analyses showed
telithromycin to be the least costly therapy in 88% of 1000 
simulations. Telithromycin was cost-effective at a threshold 
of $500/cure in 86% of simulations, and at a threshold of
$1000/cure in 83% of simulations. CONCLUSIONS:
Telithromycin appears to be a cost-effective treatment for CAP
versus amoxicillin/clauvulanate, azithromycin, clarithromycin
and ﬂuoroquinolones.
